JAMES AND MIRIAM MULVA and the Mulva Family Foundation donated $50 million to advance neuroscience at UT Austin and another $25 million for cancer research at MD Anderson Cancer Center. The total $75 million gift to the two UT institutions will advance health care in Texas and globally. The $25 million grant supports MD Anderson’s...
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
